Browsing Category
Pharma Industry News
4534 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Lilly (NYSE: LLY) now gets 65% of H1 revenue from Mounjaro and Zepbound
Mounjaro and Zepbound generated $27.69 billion for Eli Lilly and Company in H1 2026, or almost 65% of total revenue. Excluding the two tirzepatide brands, revenue grew by only about 11%.
Mapi Pharma targets cariprazine lifecycle extension with once-monthly injectable
Mapi’s monthly Cariprazine Depot clears its first safety hurdle as a $3.6bn oral franchise approaches a key 2029 patent transition.
Can a nasal therapy bypass the blood-brain barrier? NEO100’s Phase 2a data offer an early answer
NEO100 posts 48.9% six-month PFS and 26-month median survival, but NeOnc’s $2m cash balance puts funding and FDA strategy in focus.
Eli Lilly (NYSE: LLY) raises 2026 guidance as Mounjaro and Zepbound reshape pharma growth
Eli Lilly raises 2026 guidance as Mounjaro and Zepbound drive 48% Q2 revenue growth. Read how LLY’s GLP-1 scale reshapes Big Pharma.
Theriva targets Phase 2/3 VCN-01 trial after early eye-preservation signal
Theriva plans a VCN-01 Phase 2/3 retinoblastoma trial after early eye-preservation signals, but its $11.3m cash runway raises the stakes.
OPKO Health (Nasdaq: OPK) raises $125m against mazdutide royalties as GLP-1 financing strategy deepens
OPKO Health raises $125 million against mazdutide royalties. Read how the KKR-linked financing reshapes OPK’s GLP-1 capital strategy.
Rapid NOVA-2 enrollment brings LB Pharmaceuticals closer to its first potential FDA filing
LB-102 Phase 3 data move into H1 2027 as LB Pharmaceuticals deploys $150m to expand its psychiatry pipeline ahead of a pivotal test.
Sutacimig Phase 3 path puts Hemab’s $457.5m post-IPO cash base to work
Sutacimig gets an FDA-backed Phase 3 path as Hemab deploys its $457.5m post-IPO cash base. See what the pivotal trial means for growth.
Spero Therapeutics (Nasdaq: SPRO) pivots to immunology after Utebzi approval and $105m financing
Spero Therapeutics uses Utebzi royalties to fund an Innovent immunology pivot. Read how SPRO’s cash runway, CD40L bet and stock discount fit together.
Septerna’s oral hypoparathyroidism strategy gets its first human pharmacokinetic validation
SEP-479’s 3-to-4-day half-life supports once-daily dosing as Septerna targets an oral alternative in hypoparathyroidism. See what comes next.